



WHAT IS ALL THIS CURRENT FUSS ABOUT “RAS”?

Prescient Therapeutics Limited (ASX: PTX)

AusBiotech Conference November 2019

Disclaimer and safe harbor

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.



This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Corporate Snapshot —

KEY METRICS

ASX Ticker	PTX
Total Issued Capital	394.3 M shares
Options	95.4M listed PTXOC; 12.1M unlisted

Share Price ¹	A\$0.061
Market Capitalisation ¹	A\$24 M
Cash Position ²	A\$8.7 M
Top 20 Own	50%



RESEARCH COVERAGE

HC Wainwright & Co

18 March 2019


Rating: Buy

Price Target: \$0.20

Prescient's approach: address the mutations causing cancer

Cells divide over
and over

Sometimes
mistakes are made



MUTATIONS

CANCER



Why are we hearing about **Ras mutations** all of a sudden?

Vantage June 04, 2019

Asco 2019 – KRAS chase heats up with Amgen data



Madeleine Armstrong



Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.

Early cancer drug data give Amgen hope it has 'cracked KRAS code'

BRIEF

Amgen's KRAS success has other drugmakers eager to follow

Biotech

Mirati sets date for closely watched clinical KRAS readout

by Nick Paul Taylor | Oct 18, 2019 8:28am

Mirati data to test whether biotech can challenge Amgen in KRAS quest

ONCOLOGY

Notorious KRAS: Taking down cancer researchers' biggest foe

After decades of failures, the first wave of KRAS G12C inhibitors has reached the clinic. Can the feat be repeated with other RAS proteins?

by Lisa M. Jervis

...and just yesterday:

Mirati clears first clinical hurdle in KRAS race against Amgen

by Nick Paul Taylor | Oct 29, 2019 3:42am

Shares in Mirati climbed 14% in after-hours trading, adding to a valuation that had already topped \$3 billion on excitement about the potential of finally drugging KRAS. Amgen finished the day up by 1%.

Business

Amgen's 'White Whale' Cancer Data May Send Shares to Record High

By [Cristin Flanagan](#)

4 September 2019, 23:15 GMT+10

...and this morning:

Watch out, Amgen and Mirati. Boehringer's pan-KRAS inhibitor enters cancer clinical trials

by [Angus Liu](#) | Oct 30, 2019 8:42am

| What are Ras mutations?


- The first human oncogene (cancer-causing) discovered in 1982
- Remains the most common mutation causing cancer
- Over 30% of all human cancers are driven by mutant Ras proteins
 - » 95% of pancreatic cancers
 - » 45% of colorectal cancer
 - » 35% of lung cancers
 - » **3 million new cancers every year with Ras mutations!**
- Switch stuck “on” causing uncontrolled growth
- Mutant Ras tumors are often unresponsive to current treatments
- There are still no approved therapies targeting Ras

| Is Ras is still the “undruggable target”?

Despite the importance of targeting Ras, no-one has had success.


Why?

- Many different types of Ras mutations
- Ras protein is smooth with no obvious binding pockets
- Mutated Ras is very similar to normal Ras
- It occurs within the cell (not externally, where antibodies can access it)



PTX-100 has a unique way of disrupting the Ras pathway

- Targeting Ras **directly** has proven elusive
- PTX-100 disrupts the Ras pathway **downstream of Ras** (inhibits activation of Ral, Rac & Rho)
 - » “If you cannot inhibit the parent, inhibit the children”




- RhoA has subsequently become a target of interest in its own right
- PTX-100 is the **only clinical stage RhoA inhibitor globally** (in addition Ras pathway inhibition)

PTX-100 addresses many different Ras mutations




There are three Ras proteins (K, N & H)
Each one has many different mutations that drive different cancers

Competitor drugs are targeting one very specific type of Ras mutation
» KRAS G12C

PTX-100 has a unique mechanism we believe can **address all K-Ras and N-Ras mutant cancers**



— Listed Ras peers

				
Drug	AMG-510	MRTX849	G12Di	PTX-100
Inhibits	KRAS G12C	KRAS G12C	KRAS G12D	K-Ras N-Ras RhoA
Phase	Phase 1	Phase 1	Preclinical	Phase 1b
Market cap	US \$121 B	US\$3 B		A\$24 M

Market reacting to Ras developments



- Post release of ASCO data in June 2019, Amgen (NASDAQ: AMGN) reached a peak price of US\$ 211.90, appreciating by over 27%.



- On the day of Amgen's news announcement Mirati Therapeutics (NASDAQ: MRTX) also saw its shares open up 25%.
- Further, its share price appreciated by ~65% in the subsequent months to a market cap of US\$3.0 Billion.



PTX-100 trial underway

- Phase 1 trial in solid tumours previously completed – safety profile established
- Phase 1b Basket PK/PD study underway in Australia
 - » Myeloma
 - » Lymphoma
 - » Gastric cancer
 - » Pancreatic cancer
- Under leadership of globally renowned oncologist, Professor H. Miles Prince, AM
- Expected readout 2H 2020




We know the pathway that is targeted by PTX-100 is critical to the survival of the cancers included in this study.

As a cancer specialist I want to see PTX-100 added to the tool-box of targeted treatments.

Professor Miles Prince, MA

PTX-100 ...not just Ras, but also the only drug targeting RhoA

- Given unmet need, it is possible only one pivotal trial post successful Phase 1b may be required
 - » “Loxo-style” Basket heme and/or basket solid cancers enriched for RhoA & Ras mutations
 - » Faster path to commercialisation
 - » Small patient population but large potential market value




“One trial to launch”

Years and \$ saved

Presentation summary

- PTX-100 uniquely positioned in hot Ras space
- Potential advantages over competitors' approaches
- Trial commenced under leadership of Prof Miles Prince
- Potential for shorter development path
- Additional exposure to upside with PTX-200
- Funding in place
- Backing from life-science focussed funds in US and Australia

ASX CODE: PTX



Contact US

 Steven Yatomi-Clarke
CEO & Managing Director

 steven@ptxtherapeutics.com

 +61 417 601 440

 ptxtherapeutics.com